The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Omalizumab Biosimilars Market Research Report 2025
Synopsis
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Global Omalizumab Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Omalizumab Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Omalizumab Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Segment by Type
150 mg/mL
75 mg/0.5 mL
Segment by Application
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Omalizumab Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Global Omalizumab Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Omalizumab Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Omalizumab Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Segment by Type
150 mg/mL
75 mg/0.5 mL
Segment by Application
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Omalizumab Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Omalizumab Biosimilars Market Overview
1.1 Product Overview and Scope of Omalizumab Biosimilars
1.2 Omalizumab Biosimilars Segment by Type
1.2.1 Global Omalizumab Biosimilars Market Value Comparison by Type (2023-2029)
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Omalizumab Biosimilars Segment by Application
1.3.1 Global Omalizumab Biosimilars Market Value by Application: (2023-2029)
1.3.2 Persistent Asthma
1.3.3 Nasal Polyps
1.3.4 Chronic Idiopathic Urticaria
1.4 Global Omalizumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Omalizumab Biosimilars Revenue 2018-2029
1.4.2 Global Omalizumab Biosimilars Sales 2018-2029
1.4.3 Global Omalizumab Biosimilars Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Omalizumab Biosimilars Market Competition by Manufacturers
2.1 Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2018-2023)
2.2 Global Omalizumab Biosimilars Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Omalizumab Biosimilars Average Price by Manufacturers (2018-2023)
2.4 Global Omalizumab Biosimilars Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Omalizumab Biosimilars, Product Type & Application
2.7 Omalizumab Biosimilars Market Competitive Situation and Trends
2.7.1 Omalizumab Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Omalizumab Biosimilars Players Market Share by Revenue
2.7.3 Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Omalizumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Omalizumab Biosimilars Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Omalizumab Biosimilars Global Omalizumab Biosimilars Sales by Region: 2018-2029
3.2.1 Global Omalizumab Biosimilars Sales by Region: 2018-2023
3.2.2 Global Omalizumab Biosimilars Sales by Region: 2024-2029
3.3 Global Omalizumab Biosimilars Global Omalizumab Biosimilars Revenue by Region: 2018-2029
3.3.1 Global Omalizumab Biosimilars Revenue by Region: 2018-2023
3.3.2 Global Omalizumab Biosimilars Revenue by Region: 2024-2029
3.4 North America Omalizumab Biosimilars Market Facts & Figures by Country
3.4.1 North America Omalizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Omalizumab Biosimilars Sales by Country (2018-2029)
3.4.3 North America Omalizumab Biosimilars Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Omalizumab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Omalizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Omalizumab Biosimilars Sales by Country (2018-2029)
3.5.3 Europe Omalizumab Biosimilars Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Omalizumab Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Omalizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Omalizumab Biosimilars Sales by Country (2018-2029)
3.6.3 Asia Pacific Omalizumab Biosimilars Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Omalizumab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Omalizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Omalizumab Biosimilars Sales by Country (2018-2029)
3.7.3 Latin America Omalizumab Biosimilars Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Omalizumab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Omalizumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Omalizumab Biosimilars Sales by Country (2018-2029)
3.8.3 Middle East and Africa Omalizumab Biosimilars Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Omalizumab Biosimilars Sales by Type (2018-2029)
4.1.1 Global Omalizumab Biosimilars Sales by Type (2018-2023)
4.1.2 Global Omalizumab Biosimilars Sales by Type (2024-2029)
4.1.3 Global Omalizumab Biosimilars Sales Market Share by Type (2018-2029)
4.2 Global Omalizumab Biosimilars Revenue by Type (2018-2029)
4.2.1 Global Omalizumab Biosimilars Revenue by Type (2018-2023)
4.2.2 Global Omalizumab Biosimilars Revenue by Type (2024-2029)
4.2.3 Global Omalizumab Biosimilars Revenue Market Share by Type (2018-2029)
4.3 Global Omalizumab Biosimilars Price by Type (2018-2029)
5 Segment by Application
5.1 Global Omalizumab Biosimilars Sales by Application (2018-2029)
5.1.1 Global Omalizumab Biosimilars Sales by Application (2018-2023)
5.1.2 Global Omalizumab Biosimilars Sales by Application (2024-2029)
5.1.3 Global Omalizumab Biosimilars Sales Market Share by Application (2018-2029)
5.2 Global Omalizumab Biosimilars Revenue by Application (2018-2029)
5.2.1 Global Omalizumab Biosimilars Revenue by Application (2018-2023)
5.2.2 Global Omalizumab Biosimilars Revenue by Application (2024-2029)
5.2.3 Global Omalizumab Biosimilars Revenue Market Share by Application (2018-2029)
5.3 Global Omalizumab Biosimilars Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Roche Omalizumab Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Omalizumab Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Glenmark Pharmaceuticals
6.3.1 Glenmark Pharmaceuticals Corporation Information
6.3.2 Glenmark Pharmaceuticals Description and Business Overview
6.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Portfolio
6.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.4 Selexis
6.4.1 Selexis Corporation Information
6.4.2 Selexis Description and Business Overview
6.4.3 Selexis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Selexis Omalizumab Biosimilars Product Portfolio
6.4.5 Selexis Recent Developments/Updates
6.5 Generium
6.5.1 Generium Corporation Information
6.5.2 Generium Description and Business Overview
6.5.3 Generium Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Generium Omalizumab Biosimilars Product Portfolio
6.5.5 Generium Recent Developments/Updates
6.6 CuraTeQ
6.6.1 CuraTeQ Corporation Information
6.6.2 CuraTeQ Description and Business Overview
6.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.6.4 CuraTeQ Omalizumab Biosimilars Product Portfolio
6.6.5 CuraTeQ Recent Developments/Updates
6.7 Celltrion Healthcare
6.6.1 Celltrion Healthcare Corporation Information
6.6.2 Celltrion Healthcare Description and Business Overview
6.6.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Celltrion Healthcare Omalizumab Biosimilars Product Portfolio
6.7.5 Celltrion Healthcare Recent Developments/Updates
6.8 Alvotech
6.8.1 Alvotech Corporation Information
6.8.2 Alvotech Description and Business Overview
6.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Alvotech Omalizumab Biosimilars Product Portfolio
6.8.5 Alvotech Recent Developments/Updates
6.9 BiosanaPharma
6.9.1 BiosanaPharma Corporation Information
6.9.2 BiosanaPharma Description and Business Overview
6.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.9.4 BiosanaPharma Omalizumab Biosimilars Product Portfolio
6.9.5 BiosanaPharma Recent Developments/Updates
6.10 Mabpharm
6.10.1 Mabpharm Corporation Information
6.10.2 Mabpharm Description and Business Overview
6.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Mabpharm Omalizumab Biosimilars Product Portfolio
6.10.5 Mabpharm Recent Developments/Updates
6.11 CSPC Pharmaceutical Group
6.11.1 CSPC Pharmaceutical Group Corporation Information
6.11.2 CSPC Pharmaceutical Group Omalizumab Biosimilars Description and Business Overview
6.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Portfolio
6.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.12 Biomabs
6.12.1 Biomabs Corporation Information
6.12.2 Biomabs Omalizumab Biosimilars Description and Business Overview
6.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Biomabs Omalizumab Biosimilars Product Portfolio
6.12.5 Biomabs Recent Developments/Updates
6.13 HisunPharm
6.13.1 HisunPharm Corporation Information
6.13.2 HisunPharm Omalizumab Biosimilars Description and Business Overview
6.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.13.4 HisunPharm Omalizumab Biosimilars Product Portfolio
6.13.5 HisunPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Omalizumab Biosimilars Industry Chain Analysis
7.2 Omalizumab Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Omalizumab Biosimilars Production Mode & Process
7.4 Omalizumab Biosimilars Sales and Marketing
7.4.1 Omalizumab Biosimilars Sales Channels
7.4.2 Omalizumab Biosimilars Distributors
7.5 Omalizumab Biosimilars Customers
8 Omalizumab Biosimilars Market Dynamics
8.1 Omalizumab Biosimilars Industry Trends
8.2 Omalizumab Biosimilars Market Drivers
8.3 Omalizumab Biosimilars Market Challenges
8.4 Omalizumab Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
